1Gaucher disease. Current issues in diagnosis and treatment. NIH technology assessment panel on gaucher disease [ J ]. JAMA, 1996,275 ( 7 ) : 548-553.
2MANKIN H J, ROSENTHAL D I, XAVIER R. Gaucher disease, New approaches to an ancient disease[ J]. J Bone Joint Surg Am, 2001, 83-A(5) : 748-762.
3BRADY R D, KANFER J N, SHAPIRO D. Metabolism of glucocerebrosidese vidence of enzymatic deficiency in Gaucher' s disease [ J ]. Biochem Biophys Res Commun, 1965, 18:221-225.
4GRABOWSKI G A, LESLIE N, WENSTRUP R. Enzyme therapy for Gaucher disease: the first 5 years[ J]. Blood Rev, 1998, 12 (2) : 115-133.
5VELLODI A, BEMBI B, DE VILLEMEUR T, et al. Management of neuronopathic Gaucher disease: A European consensus[ J]. J Inherit Metab Dis, 2001, 24 (3) :319-327.
6CHOY F Y M, HUMPHRIES M L, SHI H P. Identification of two novel fouruncommon missense mutation among Chinese Gaucher disease patients[J]. Am J Med Genet, 1997 , 71 (2) :172- 178.
7BRADY R O . Enzyme replacement therapy: conception, chaos and culmination [ J ]. Phil Trans R Soc Lond B, 2003, 358 ( 1433 ) :915-916.
8GRABOWSKI G A , BARTON N W , PASTORES G, et al. Enzyme therapy in type I Gaucher disease : comparative efficacy of mannose-terminated , glucocerebrosidase from natural and recombinant sources [J]. Ann Intern Med, 1995, 122(1) : 33-39.
9DE FOST M, VOM DAHL S, WEVERLING G J, et al. Increased incidence of cancer in adult Gaucher disease in Western Europe[J]. Blood Cells Mol Dis, 2006, 36(1 ) :53-58.
10MISTRY P K, WRAIGHT E P, COX T M. In vivo distribution of mannose-terminated human glucocerebrosidase in patients with Gaucher disease. In: NIH Technology Assessment Conference on Gaucher Disease: Current Issues in Diagnosis and Treatment[ C ]. 1995; Bethesda, MD: National Institutes of Health 1995: 91.
2Weinreb NJ,Charrow J,Andersson HC,et al.Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment:a report from the Gaucher Rigistry.Am J Med,2002,113:112-119.
3Charrow J,Andersson HC,Kaplan P,et al.Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease:consensus recommendations.J Pediatr,2004,114:116.
4Barton NW,Brady RO,Dambrosia JM,et al.Replacement therapy for inherited enzyme deficiency:Macrophage-targeted glucocerebrosidase for Gaucher's disease.N Engl J Med,1991,324:1464-1470.
5Beutler E,Kay A,Saven A,et al.Enzyme replacement therapy for gaucher disease.Blood,1991,78:1183-1189.
6Brady RO.Enzyme replacement therapy:conception,chaos and culmination.Phil Trans R Soc Lond B,2003,358:915-916.
7Grabowski GA,Barton NW,Pastores G,et al.Enzyme therapy in type 1 Gaucher disease:comparative efficacy of mannose-terminated,glucocerebrosidase from natural and recombinant sources.Ann Intern Med,1995,122:33-39.
8Pastores G,Sibille AR,Grabowski GA.Enzyme therapy in Gaucher disease type 1; dosage,efficasy,and adverse effects in 33 patients treated for 6 to 24 months.Blood,1993,82:408-416.
9Grabowski GA,Leslie N,Wenstrup RJ.Enzyme therapy for Gaucher disease:the first 5 years.Blood Rev,1998,12:115-133.
10Grabowski GA.Recent clinical progress in Gaucher disease.Curr Opin Pediatr,2005,17:519-524.
